

Speaker Biographies

Brian O'Mahony

Chief Executive, Irish Haemophilia Society Ltd.

Brian O'Mahony is the Chief Executive of the Irish Haemophilia Society and the President of the European Haemophilia Consortium. He represents the society on the statutory National Haemophilia Council and he is the Vice Chair of the Tender Commission established by the Irish Government for the Procurement of Factor Concentrates. He is a member of the Board of the Irish Blood Transfusion Service, the Irish vCJD incident panel and the National Clinical Advisory Group on Hepatitis C. He previously served as Chair of the Irish Haemophilia Society for 17 years and as President of the WFH for 10 years from 1994 to 2004. His publications for WFH include Monographs on Advocacy, Developing Haemophilia Organisations, Economics and Health Technology Assessments and a Guidebook on National Tender systems. His scientific publications include papers on prophylaxis, surveys of Haemophilia care in Europe, consensus papers on blood and plasma issues and papers on the economics of Haemophilia care. A medical scientist by profession, he is also the convenor of the Plasma Users Coalition (PLUS) which advocates on plasma and blood related issues with the European Commission on behalf of several non governmental organisations. He is an adjunct Professor of Health Service Management at Trinity College, Dublin. Brian has severe Haemophilia B.

Akin Akinc, Ph.D.

Vice President, General Manager, Hemophilia Program

Dr. Akinc joined Alnylam in 2003 and has served in roles of increasing responsibility and leadership in the research organization. During his time at Alnylam he has led the formulation group and has served as co-leader for interdisciplinary efforts focused on delivery of RNAi therapeutics and the development of RNAi platform technology. Akin has also contributed to Alnylam's therapeutic programs, having served as Program Leader for multiple programs. He has led the fitusiran program from discovery to its current clinical stage. Akin received his B.S.E in Chemical Engineering from Princeton University and his Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology.

Benny Sorensen, M.D., Ph.D.

Senior Director, Clinical Research

Dr. Sorensen joined Alnylam in 2013 with more than 15 years of experience in clinical and academic hemophilia and hemostasis research and management. Before joining Alnylam, Dr. Sorensen was a Global Medical Director at Baxter Healthcare Corporation, where he was responsible for developing clinical, regulatory, commercial, and business development strategies for hemophilia products and services. Prior to Baxter he was the Director of the Haemostasis Research Unit and Honorary Lecturer at Guy's and St. Thomas' Hospital & King's College London School of Medicine, where he led the advancement of several clinical trials across Phases I, II, and III. Dr. Sorensen has published extensively on the topics of hemophilia and hemostasis management.